| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver Transplantation | 63 | 2024 | 1175 | 8.990 |
Why?
|
| Tissue and Organ Procurement | 20 | 2025 | 358 | 4.640 |
Why?
|
| Kidney Transplantation | 22 | 2025 | 855 | 4.390 |
Why?
|
| Tissue Donors | 24 | 2025 | 504 | 3.810 |
Why?
|
| Graft Survival | 38 | 2025 | 907 | 3.660 |
Why?
|
| Kidney Failure, Chronic | 7 | 2025 | 414 | 1.800 |
Why?
|
| Graft Rejection | 16 | 2025 | 1076 | 1.530 |
Why?
|
| Waiting Lists | 10 | 2023 | 186 | 1.440 |
Why?
|
| Liver Failure | 7 | 2023 | 68 | 1.430 |
Why?
|
| Hepatitis C | 7 | 2019 | 174 | 1.280 |
Why?
|
| End Stage Liver Disease | 4 | 2024 | 61 | 1.200 |
Why?
|
| Living Donors | 9 | 2024 | 339 | 1.140 |
Why?
|
| Liver Diseases | 6 | 2020 | 242 | 1.110 |
Why?
|
| Carcinoma, Hepatocellular | 6 | 2012 | 399 | 1.090 |
Why?
|
| Liver Cirrhosis | 5 | 2014 | 257 | 1.060 |
Why?
|
| Kidney | 5 | 2023 | 1148 | 1.000 |
Why?
|
| Survival Rate | 20 | 2025 | 1898 | 1.000 |
Why?
|
| Retrospective Studies | 39 | 2025 | 9185 | 0.980 |
Why?
|
| Liver Neoplasms | 6 | 2012 | 755 | 0.930 |
Why?
|
| Liver Failure, Acute | 3 | 2009 | 39 | 0.860 |
Why?
|
| Humans | 89 | 2025 | 89864 | 0.780 |
Why?
|
| Death | 6 | 2020 | 89 | 0.780 |
Why?
|
| T-Lymphocytes, Regulatory | 4 | 2013 | 312 | 0.780 |
Why?
|
| Liver | 10 | 2021 | 1211 | 0.740 |
Why?
|
| Risk Factors | 20 | 2025 | 5548 | 0.730 |
Why?
|
| Risk Assessment | 11 | 2020 | 2324 | 0.670 |
Why?
|
| Male | 52 | 2025 | 42614 | 0.640 |
Why?
|
| Postoperative Complications | 7 | 2012 | 2301 | 0.640 |
Why?
|
| Adult | 35 | 2025 | 26784 | 0.640 |
Why?
|
| Follow-Up Studies | 15 | 2025 | 3670 | 0.640 |
Why?
|
| Forkhead Transcription Factors | 3 | 2013 | 171 | 0.640 |
Why?
|
| Transplantation, Homologous | 8 | 2010 | 995 | 0.630 |
Why?
|
| Portal Vein | 3 | 2010 | 121 | 0.630 |
Why?
|
| Liver Circulation | 2 | 2010 | 29 | 0.620 |
Why?
|
| Transplant Recipients | 1 | 2020 | 140 | 0.620 |
Why?
|
| Female | 52 | 2025 | 46529 | 0.600 |
Why?
|
| Fatty Liver | 3 | 2010 | 98 | 0.590 |
Why?
|
| Models, Statistical | 2 | 2013 | 576 | 0.590 |
Why?
|
| Obesity | 4 | 2024 | 972 | 0.580 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2009 | 1350 | 0.570 |
Why?
|
| Diabetes Mellitus | 1 | 2024 | 744 | 0.550 |
Why?
|
| Immune Tolerance | 3 | 2013 | 341 | 0.540 |
Why?
|
| Donor Selection | 4 | 2025 | 76 | 0.540 |
Why?
|
| Patient Selection | 6 | 2012 | 682 | 0.530 |
Why?
|
| Middle Aged | 35 | 2025 | 26103 | 0.530 |
Why?
|
| Transplantation Tolerance | 2 | 2008 | 138 | 0.520 |
Why?
|
| Aged | 22 | 2024 | 19230 | 0.510 |
Why?
|
| Treatment Outcome | 21 | 2024 | 8264 | 0.500 |
Why?
|
| Severity of Illness Index | 9 | 2023 | 1858 | 0.500 |
Why?
|
| Dendritic Cells | 3 | 2013 | 451 | 0.490 |
Why?
|
| Child, Preschool | 14 | 2024 | 3765 | 0.470 |
Why?
|
| Prognosis | 12 | 2025 | 3789 | 0.460 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 3 | 2013 | 37 | 0.460 |
Why?
|
| Child | 17 | 2024 | 7233 | 0.450 |
Why?
|
| Length of Stay | 3 | 2013 | 745 | 0.450 |
Why?
|
| Hepatic Artery | 3 | 2012 | 84 | 0.440 |
Why?
|
| Adolescent | 18 | 2024 | 9327 | 0.430 |
Why?
|
| Polymorphism, Genetic | 2 | 2006 | 825 | 0.410 |
Why?
|
| Graft vs Host Disease | 2 | 2021 | 358 | 0.400 |
Why?
|
| Hepacivirus | 6 | 2019 | 131 | 0.400 |
Why?
|
| United States | 14 | 2023 | 7094 | 0.380 |
Why?
|
| Health Status Indicators | 1 | 2012 | 103 | 0.380 |
Why?
|
| Thinness | 2 | 2010 | 45 | 0.380 |
Why?
|
| Reoperation | 5 | 2023 | 604 | 0.380 |
Why?
|
| Perfusion | 2 | 2020 | 253 | 0.380 |
Why?
|
| Infant | 13 | 2024 | 3187 | 0.380 |
Why?
|
| Survival Analysis | 6 | 2014 | 1497 | 0.370 |
Why?
|
| Antigens, CD | 3 | 2008 | 466 | 0.360 |
Why?
|
| Drug Therapy, Computer-Assisted | 1 | 2010 | 8 | 0.360 |
Why?
|
| Cause of Death | 4 | 2020 | 269 | 0.360 |
Why?
|
| Critical Care | 2 | 2020 | 384 | 0.350 |
Why?
|
| Biopsy, Needle | 3 | 2012 | 231 | 0.340 |
Why?
|
| Drug Monitoring | 1 | 2010 | 118 | 0.330 |
Why?
|
| Delayed Graft Function | 3 | 2025 | 14 | 0.330 |
Why?
|
| Preoperative Care | 2 | 2009 | 395 | 0.330 |
Why?
|
| Adoptive Transfer | 2 | 2006 | 169 | 0.330 |
Why?
|
| Renal Dialysis | 2 | 2024 | 337 | 0.330 |
Why?
|
| Multivariate Analysis | 6 | 2019 | 983 | 0.320 |
Why?
|
| Acetaminophen | 2 | 2006 | 57 | 0.320 |
Why?
|
| Prospective Studies | 8 | 2018 | 4322 | 0.320 |
Why?
|
| Chemoembolization, Therapeutic | 1 | 2009 | 35 | 0.320 |
Why?
|
| Body Mass Index | 4 | 2024 | 776 | 0.310 |
Why?
|
| Constriction, Pathologic | 2 | 2006 | 222 | 0.310 |
Why?
|
| Fatigue | 1 | 2009 | 173 | 0.310 |
Why?
|
| Medical Errors | 1 | 2009 | 115 | 0.310 |
Why?
|
| Thrombosis | 2 | 2012 | 302 | 0.300 |
Why?
|
| Young Adult | 11 | 2020 | 6389 | 0.300 |
Why?
|
| Kaplan-Meier Estimate | 5 | 2024 | 854 | 0.300 |
Why?
|
| Transplants | 2 | 2018 | 42 | 0.300 |
Why?
|
| Time Factors | 10 | 2019 | 5357 | 0.290 |
Why?
|
| Organ Preservation | 2 | 2025 | 119 | 0.280 |
Why?
|
| Proportional Hazards Models | 8 | 2024 | 848 | 0.280 |
Why?
|
| Incidence | 8 | 2019 | 1600 | 0.280 |
Why?
|
| Compartment Syndromes | 1 | 2006 | 13 | 0.270 |
Why?
|
| Lymphocytic choriomeningitis virus | 1 | 2006 | 14 | 0.270 |
Why?
|
| Lymphocytic Choriomeningitis | 1 | 2006 | 9 | 0.270 |
Why?
|
| Aged, 80 and over | 5 | 2023 | 6779 | 0.270 |
Why?
|
| Diagnostic Techniques, Cardiovascular | 1 | 2006 | 12 | 0.270 |
Why?
|
| Hepatitis | 1 | 2006 | 34 | 0.270 |
Why?
|
| Biliary Atresia | 1 | 2006 | 22 | 0.270 |
Why?
|
| Catheter Ablation | 1 | 2009 | 254 | 0.270 |
Why?
|
| Aprotinin | 1 | 2006 | 26 | 0.270 |
Why?
|
| Liver Regeneration | 1 | 2006 | 36 | 0.270 |
Why?
|
| Survival | 1 | 2006 | 21 | 0.270 |
Why?
|
| Serine Proteinase Inhibitors | 1 | 2006 | 28 | 0.270 |
Why?
|
| Bile Ducts | 1 | 2006 | 60 | 0.270 |
Why?
|
| Mannose-Binding Lectin | 1 | 2006 | 3 | 0.270 |
Why?
|
| Cholecystectomy | 1 | 2006 | 22 | 0.260 |
Why?
|
| Antigens, Differentiation | 1 | 2006 | 141 | 0.260 |
Why?
|
| Hemochromatosis | 1 | 2006 | 11 | 0.260 |
Why?
|
| Ferric Compounds | 1 | 2006 | 38 | 0.260 |
Why?
|
| Abdomen | 1 | 2006 | 124 | 0.260 |
Why?
|
| Hemostatics | 1 | 2006 | 58 | 0.260 |
Why?
|
| Staining and Labeling | 1 | 2006 | 169 | 0.260 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2006 | 55 | 0.260 |
Why?
|
| Antigen-Presenting Cells | 1 | 2006 | 142 | 0.260 |
Why?
|
| Ascites | 1 | 2006 | 56 | 0.260 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2006 | 111 | 0.260 |
Why?
|
| Exercise Therapy | 1 | 2006 | 82 | 0.260 |
Why?
|
| Enterocolitis, Pseudomembranous | 1 | 2006 | 52 | 0.260 |
Why?
|
| Quality of Health Care | 2 | 2006 | 387 | 0.250 |
Why?
|
| Viral Envelope Proteins | 1 | 2006 | 94 | 0.250 |
Why?
|
| Brain Death | 5 | 2020 | 83 | 0.250 |
Why?
|
| Albumins | 1 | 2006 | 129 | 0.250 |
Why?
|
| Hepatitis B | 1 | 2006 | 76 | 0.250 |
Why?
|
| Steroids | 1 | 2006 | 173 | 0.250 |
Why?
|
| Immune System | 1 | 2006 | 97 | 0.250 |
Why?
|
| Th2 Cells | 1 | 2006 | 147 | 0.250 |
Why?
|
| Surgical Mesh | 1 | 2006 | 124 | 0.250 |
Why?
|
| Serotonin | 1 | 2006 | 221 | 0.250 |
Why?
|
| Hepatocytes | 1 | 2006 | 122 | 0.240 |
Why?
|
| Herniorrhaphy | 1 | 2006 | 91 | 0.240 |
Why?
|
| Vascular Diseases | 1 | 2006 | 118 | 0.240 |
Why?
|
| Metabolic Syndrome | 1 | 2006 | 123 | 0.240 |
Why?
|
| Intubation, Intratracheal | 1 | 2006 | 147 | 0.240 |
Why?
|
| Infant, Newborn | 6 | 2024 | 2498 | 0.240 |
Why?
|
| HLA Antigens | 1 | 2006 | 227 | 0.240 |
Why?
|
| Bacterial Infections | 1 | 2006 | 184 | 0.230 |
Why?
|
| Endothelium, Vascular | 1 | 2006 | 435 | 0.230 |
Why?
|
| Palliative Care | 1 | 2006 | 264 | 0.220 |
Why?
|
| Critical Illness | 1 | 2006 | 311 | 0.220 |
Why?
|
| Liver Function Tests | 4 | 2010 | 92 | 0.220 |
Why?
|
| Body Surface Area | 1 | 2023 | 36 | 0.220 |
Why?
|
| Intention to Treat Analysis | 1 | 2023 | 72 | 0.220 |
Why?
|
| Stents | 1 | 2006 | 412 | 0.220 |
Why?
|
| Immunity, Innate | 1 | 2006 | 433 | 0.210 |
Why?
|
| Immunosuppressive Agents | 3 | 2010 | 977 | 0.210 |
Why?
|
| Organ Transplantation | 1 | 2006 | 281 | 0.210 |
Why?
|
| Mice, Inbred C3H | 3 | 2008 | 371 | 0.210 |
Why?
|
| Policy | 1 | 2022 | 35 | 0.200 |
Why?
|
| Cohort Studies | 7 | 2020 | 2886 | 0.200 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2009 | 2676 | 0.200 |
Why?
|
| Residence Characteristics | 1 | 2024 | 203 | 0.200 |
Why?
|
| Proteome | 2 | 2014 | 135 | 0.200 |
Why?
|
| Geography | 1 | 2022 | 227 | 0.190 |
Why?
|
| Socioeconomic Factors | 1 | 2024 | 594 | 0.190 |
Why?
|
| Insulin | 1 | 2006 | 1148 | 0.180 |
Why?
|
| Hypertension | 1 | 2006 | 747 | 0.180 |
Why?
|
| Health Policy | 1 | 2022 | 188 | 0.180 |
Why?
|
| Acute Kidney Injury | 1 | 2025 | 316 | 0.180 |
Why?
|
| Social Class | 1 | 2020 | 137 | 0.170 |
Why?
|
| Washington | 3 | 2024 | 49 | 0.170 |
Why?
|
| Age Factors | 6 | 2024 | 1880 | 0.170 |
Why?
|
| Databases, Factual | 4 | 2019 | 864 | 0.170 |
Why?
|
| Cold Ischemia | 3 | 2010 | 19 | 0.170 |
Why?
|
| Mice | 7 | 2013 | 11846 | 0.170 |
Why?
|
| Insurance, Health | 1 | 2020 | 164 | 0.170 |
Why?
|
| Laparoscopy | 1 | 2006 | 777 | 0.160 |
Why?
|
| Terminal Care | 1 | 2020 | 137 | 0.160 |
Why?
|
| Body Weight | 3 | 2010 | 453 | 0.160 |
Why?
|
| Health Status Disparities | 1 | 2020 | 191 | 0.150 |
Why?
|
| Hepatitis C Antibodies | 1 | 2018 | 6 | 0.150 |
Why?
|
| Tacrolimus | 2 | 2010 | 369 | 0.150 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2008 | 2360 | 0.150 |
Why?
|
| Predictive Value of Tests | 3 | 2008 | 1729 | 0.150 |
Why?
|
| Quality Control | 1 | 2018 | 117 | 0.150 |
Why?
|
| Blood Flow Velocity | 2 | 2010 | 200 | 0.150 |
Why?
|
| Animals | 9 | 2013 | 27516 | 0.150 |
Why?
|
| Histocompatibility Testing | 2 | 2008 | 137 | 0.150 |
Why?
|
| Medicaid | 1 | 2020 | 238 | 0.150 |
Why?
|
| Antilymphocyte Serum | 1 | 1997 | 70 | 0.150 |
Why?
|
| Muromonab-CD3 | 1 | 1997 | 69 | 0.150 |
Why?
|
| Logistic Models | 3 | 2010 | 1214 | 0.140 |
Why?
|
| Erythrocyte Transfusion | 1 | 2018 | 73 | 0.140 |
Why?
|
| CTLA-4 Antigen | 2 | 2008 | 140 | 0.140 |
Why?
|
| Probability | 2 | 2009 | 350 | 0.140 |
Why?
|
| Intestines | 2 | 2010 | 416 | 0.140 |
Why?
|
| Cell Transplantation | 2 | 2006 | 47 | 0.130 |
Why?
|
| Needs Assessment | 2 | 2009 | 161 | 0.130 |
Why?
|
| Mice, Inbred Strains | 2 | 2006 | 308 | 0.130 |
Why?
|
| Glucose Tolerance Test | 2 | 2006 | 227 | 0.130 |
Why?
|
| Healthcare Disparities | 1 | 2020 | 431 | 0.130 |
Why?
|
| Proteomics | 2 | 2014 | 232 | 0.120 |
Why?
|
| Registries | 3 | 2010 | 803 | 0.110 |
Why?
|
| Case-Control Studies | 1 | 2018 | 1864 | 0.110 |
Why?
|
| CD4 Antigens | 1 | 2013 | 83 | 0.110 |
Why?
|
| Cyclosporine | 2 | 2008 | 238 | 0.110 |
Why?
|
| Methylprednisolone | 2 | 2006 | 64 | 0.100 |
Why?
|
| Decision Making | 1 | 2018 | 669 | 0.100 |
Why?
|
| Protein Array Analysis | 1 | 2012 | 52 | 0.100 |
Why?
|
| Cytomegalovirus Infections | 2 | 2006 | 150 | 0.100 |
Why?
|
| B7-H1 Antigen | 1 | 2013 | 278 | 0.090 |
Why?
|
| Heart Transplantation | 2 | 2006 | 728 | 0.090 |
Why?
|
| Medical Futility | 1 | 2010 | 31 | 0.090 |
Why?
|
| RNA, Viral | 2 | 2010 | 318 | 0.090 |
Why?
|
| Mice, Inbred C57BL | 2 | 2008 | 3250 | 0.090 |
Why?
|
| Intraoperative Period | 1 | 2010 | 91 | 0.090 |
Why?
|
| Factor Analysis, Statistical | 1 | 2010 | 114 | 0.090 |
Why?
|
| Gastroschisis | 1 | 2010 | 13 | 0.090 |
Why?
|
| Reperfusion | 1 | 2010 | 32 | 0.090 |
Why?
|
| Intestinal Volvulus | 1 | 2010 | 10 | 0.090 |
Why?
|
| Transplantation | 1 | 2010 | 38 | 0.080 |
Why?
|
| Short Bowel Syndrome | 1 | 2010 | 38 | 0.080 |
Why?
|
| Hepatitis C, Chronic | 1 | 2010 | 91 | 0.080 |
Why?
|
| DNA, Viral | 1 | 2010 | 263 | 0.080 |
Why?
|
| Intestinal Diseases | 1 | 2010 | 79 | 0.080 |
Why?
|
| Bilirubin | 1 | 2009 | 131 | 0.080 |
Why?
|
| Antiviral Agents | 2 | 2006 | 482 | 0.080 |
Why?
|
| Allografts | 2 | 2020 | 184 | 0.080 |
Why?
|
| Kidney Function Tests | 2 | 2025 | 115 | 0.080 |
Why?
|
| Enterocolitis, Necrotizing | 1 | 2010 | 80 | 0.080 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2008 | 44 | 0.080 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2008 | 79 | 0.080 |
Why?
|
| Calcineurin Inhibitors | 1 | 2008 | 53 | 0.080 |
Why?
|
| Workload | 1 | 2009 | 129 | 0.080 |
Why?
|
| Bile Duct Diseases | 1 | 2008 | 23 | 0.080 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2010 | 201 | 0.070 |
Why?
|
| Intraoperative Complications | 1 | 2009 | 185 | 0.070 |
Why?
|
| Interleukin-4 | 1 | 2008 | 129 | 0.070 |
Why?
|
| Risk | 3 | 2019 | 657 | 0.070 |
Why?
|
| Cost-Benefit Analysis | 1 | 2010 | 466 | 0.070 |
Why?
|
| ROC Curve | 1 | 2010 | 778 | 0.070 |
Why?
|
| Quality of Life | 2 | 2006 | 1680 | 0.070 |
Why?
|
| Population Surveillance | 1 | 2008 | 216 | 0.070 |
Why?
|
| CD4-CD8 Ratio | 1 | 2006 | 18 | 0.070 |
Why?
|
| Mice, Obese | 1 | 2006 | 44 | 0.070 |
Why?
|
| Nuclear Magnetic Resonance, Biomolecular | 1 | 2006 | 61 | 0.070 |
Why?
|
| Warm Ischemia | 1 | 2006 | 32 | 0.070 |
Why?
|
| Bezafibrate | 1 | 2006 | 5 | 0.070 |
Why?
|
| Major Histocompatibility Complex | 1 | 2006 | 84 | 0.070 |
Why?
|
| Hepatic Encephalopathy | 1 | 2006 | 39 | 0.070 |
Why?
|
| Polypropylenes | 1 | 2006 | 23 | 0.070 |
Why?
|
| Electrophoresis, Gel, Pulsed-Field | 1 | 2006 | 20 | 0.070 |
Why?
|
| Microcirculation | 1 | 2006 | 105 | 0.070 |
Why?
|
| Homozygote | 1 | 2006 | 201 | 0.070 |
Why?
|
| Regional Blood Flow | 1 | 2006 | 198 | 0.070 |
Why?
|
| Leptin | 1 | 2006 | 102 | 0.070 |
Why?
|
| Immunohistochemistry | 2 | 2012 | 1799 | 0.070 |
Why?
|
| Multicenter Studies as Topic | 1 | 2006 | 168 | 0.070 |
Why?
|
| Metabolic Diseases | 1 | 2006 | 50 | 0.070 |
Why?
|
| Restriction Mapping | 1 | 2006 | 154 | 0.070 |
Why?
|
| Blood Chemical Analysis | 1 | 2006 | 41 | 0.070 |
Why?
|
| T-Lymphocytes | 2 | 2006 | 1221 | 0.070 |
Why?
|
| Cytomegalovirus | 1 | 2006 | 79 | 0.070 |
Why?
|
| Models, Theoretical | 1 | 2009 | 493 | 0.070 |
Why?
|
| Chimera | 1 | 2006 | 56 | 0.070 |
Why?
|
| Glucose Intolerance | 1 | 2006 | 94 | 0.070 |
Why?
|
| Transforming Growth Factor beta | 1 | 2008 | 326 | 0.070 |
Why?
|
| Interleukin-10 | 1 | 2006 | 155 | 0.060 |
Why?
|
| Portasystemic Shunt, Transjugular Intrahepatic | 1 | 2006 | 41 | 0.060 |
Why?
|
| Cricetinae | 1 | 2006 | 558 | 0.060 |
Why?
|
| Herpesvirus 4, Human | 1 | 2006 | 120 | 0.060 |
Why?
|
| Confidence Intervals | 1 | 2006 | 221 | 0.060 |
Why?
|
| Psychology | 1 | 2005 | 25 | 0.060 |
Why?
|
| Up-Regulation | 1 | 2008 | 726 | 0.060 |
Why?
|
| Heterozygote | 1 | 2006 | 373 | 0.060 |
Why?
|
| Hypolipidemic Agents | 1 | 2006 | 99 | 0.060 |
Why?
|
| Spleen | 1 | 2006 | 433 | 0.060 |
Why?
|
| Long-Term Care | 1 | 2006 | 61 | 0.060 |
Why?
|
| Linear Models | 1 | 2006 | 421 | 0.060 |
Why?
|
| Mice, SCID | 1 | 2006 | 259 | 0.060 |
Why?
|
| Disease Outbreaks | 1 | 2006 | 156 | 0.060 |
Why?
|
| Infusions, Intravenous | 1 | 2006 | 416 | 0.060 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2006 | 315 | 0.060 |
Why?
|
| Reperfusion Injury | 1 | 2006 | 144 | 0.060 |
Why?
|
| Diarrhea | 1 | 2006 | 178 | 0.060 |
Why?
|
| Drug Overdose | 1 | 2006 | 78 | 0.060 |
Why?
|
| Education, Medical, Continuing | 1 | 2006 | 106 | 0.060 |
Why?
|
| Killer Cells, Natural | 1 | 2006 | 276 | 0.060 |
Why?
|
| Suicide, Attempted | 1 | 2006 | 135 | 0.060 |
Why?
|
| Monocytes | 1 | 2006 | 221 | 0.060 |
Why?
|
| Transplantation, Autologous | 1 | 2006 | 347 | 0.060 |
Why?
|
| Transplantation, Heterologous | 1 | 2006 | 368 | 0.060 |
Why?
|
| Catheterization | 1 | 2006 | 237 | 0.060 |
Why?
|
| Perioperative Care | 1 | 2006 | 168 | 0.060 |
Why?
|
| Haplotypes | 1 | 2006 | 637 | 0.060 |
Why?
|
| Autoimmune Diseases | 1 | 2006 | 250 | 0.060 |
Why?
|
| Postoperative Care | 1 | 2005 | 231 | 0.060 |
Why?
|
| Drug Administration Schedule | 1 | 2006 | 865 | 0.060 |
Why?
|
| Species Specificity | 1 | 2006 | 685 | 0.060 |
Why?
|
| Biomarkers | 1 | 2010 | 1774 | 0.060 |
Why?
|
| Gene Expression | 1 | 2008 | 1309 | 0.060 |
Why?
|
| Radiography | 1 | 2006 | 808 | 0.060 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2006 | 346 | 0.060 |
Why?
|
| Insulin Resistance | 1 | 2006 | 353 | 0.060 |
Why?
|
| Glomerular Filtration Rate | 1 | 2025 | 277 | 0.050 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2006 | 449 | 0.050 |
Why?
|
| Genetic Variation | 1 | 2010 | 1380 | 0.050 |
Why?
|
| Alleles | 1 | 2006 | 1139 | 0.050 |
Why?
|
| Chromatography, Liquid | 2 | 2014 | 106 | 0.050 |
Why?
|
| Intensive Care Units | 1 | 2006 | 398 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2006 | 840 | 0.050 |
Why?
|
| Mass Spectrometry | 2 | 2014 | 194 | 0.050 |
Why?
|
| Cytokines | 1 | 2006 | 811 | 0.050 |
Why?
|
| Portacaval Shunt, Surgical | 1 | 2001 | 8 | 0.050 |
Why?
|
| Education, Medical, Graduate | 1 | 2006 | 401 | 0.050 |
Why?
|
| Apoptosis | 1 | 2008 | 1717 | 0.050 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2006 | 480 | 0.050 |
Why?
|
| Area Under Curve | 1 | 2021 | 338 | 0.050 |
Why?
|
| Cells, Cultured | 1 | 2006 | 2887 | 0.050 |
Why?
|
| Recurrence | 3 | 2012 | 1144 | 0.040 |
Why?
|
| Biopsy | 2 | 2010 | 1184 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 1 | 2006 | 1394 | 0.040 |
Why?
|
| Advance Care Planning | 1 | 2020 | 45 | 0.040 |
Why?
|
| Shock | 1 | 2020 | 44 | 0.040 |
Why?
|
| Rats | 1 | 2006 | 4048 | 0.040 |
Why?
|
| Cell Differentiation | 1 | 2006 | 1532 | 0.040 |
Why?
|
| Machine Learning | 1 | 2021 | 270 | 0.040 |
Why?
|
| Cadaver | 1 | 2019 | 186 | 0.040 |
Why?
|
| Disease Models, Animal | 1 | 2006 | 2392 | 0.040 |
Why?
|
| Venous Thrombosis | 1 | 2001 | 255 | 0.040 |
Why?
|
| Erythrocyte Count | 1 | 2018 | 22 | 0.040 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2006 | 2414 | 0.040 |
Why?
|
| Plasma | 1 | 2018 | 51 | 0.040 |
Why?
|
| Acyclovir | 1 | 1997 | 108 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2009 | 3468 | 0.030 |
Why?
|
| Azathioprine | 1 | 1997 | 124 | 0.030 |
Why?
|
| Disease Progression | 2 | 2012 | 1469 | 0.030 |
Why?
|
| Acute Disease | 1 | 1997 | 846 | 0.030 |
Why?
|
| Glucocorticoids | 1 | 1997 | 357 | 0.030 |
Why?
|
| Mutation | 1 | 2006 | 4164 | 0.030 |
Why?
|
| Ions | 1 | 2014 | 75 | 0.030 |
Why?
|
| Sampling Studies | 1 | 2012 | 72 | 0.030 |
Why?
|
| Thrombophilia | 1 | 2012 | 23 | 0.030 |
Why?
|
| Models, Animal | 1 | 2013 | 277 | 0.020 |
Why?
|
| Hospitals, Pediatric | 1 | 2012 | 117 | 0.020 |
Why?
|
| Reference Values | 1 | 2012 | 662 | 0.020 |
Why?
|
| Serum | 1 | 2010 | 25 | 0.020 |
Why?
|
| Hemorrhage | 1 | 2012 | 287 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2010 | 305 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2010 | 358 | 0.020 |
Why?
|
| Genotype | 2 | 2008 | 1853 | 0.020 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2012 | 332 | 0.020 |
Why?
|
| Health Care Rationing | 1 | 2010 | 83 | 0.020 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2010 | 206 | 0.020 |
Why?
|
| Oxidative Stress | 1 | 2012 | 458 | 0.020 |
Why?
|
| Cytochrome P-450 CYP2C8 | 1 | 2008 | 3 | 0.020 |
Why?
|
| 8,11,14-Eicosatrienoic Acid | 1 | 2008 | 12 | 0.020 |
Why?
|
| Arachidonic Acid | 1 | 2008 | 63 | 0.020 |
Why?
|
| Overweight | 1 | 2009 | 119 | 0.020 |
Why?
|
| Demography | 1 | 2008 | 183 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2012 | 2018 | 0.020 |
Why?
|
| Sex Factors | 1 | 2010 | 1074 | 0.020 |
Why?
|
| Lymph Nodes | 1 | 2010 | 550 | 0.020 |
Why?
|
| Kinetics | 1 | 2008 | 1534 | 0.020 |
Why?
|
| Portal System | 1 | 2001 | 13 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 1997 | 1168 | 0.010 |
Why?
|